Protagonist Announces Icotrokinra Application for Approval in Plaque Psoriasis Submitted to the European Medicines Agency
Icotrokinra is a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor 1Filing based on four Phase 3...
CBIH Announces New Patent Initiative Targeting Opioid Addiction Through Endocannabinoid Pathways